OncoC4 merged with AcroImmune
An all-stock transaction between OncoC4, a biopharmaceutical business in its late stages, and AcroImmune has been completed. OncoC4 strengthens its development by adding two critical drug candidates, AI-061, a PD-1/VEGF...
Read More